Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes.

ABSTRACT:

Purpose

To report the safety and effectiveness of intravitreal aflibercept (IVT-AFL) for diabetic macular edema (DME) in the real-world clinical practice setting in Japan.

Methods

In this prospective, multicenter, observational, post-marketing surveillance, patients with DME newly receiving IVT-AFL were enrolled. During a 24-month follow-up, the primary outcome was the occurrence of safety events. Other pre-specified endpoints were effectiveness indicators, such as best-corrected visual acuity (BCVA), central retinal thickness, and injection frequency.

Results

In total, 646 patients administered at least one IVT-AFL injection were included in the safety analysis. During the follow-up period, adverse events occurred in 42 patients (6.50%), whereas adverse drug reaction

SUBMITTER: Sugimoto M 

PROVIDER: S-EPMC9581854 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature